New womb cancer treatment to benefit hundreds of patients each year
A drug which could buy women with advanced or recurring womb cancer more time with their loved ones before the disease progresses is to be made available on the NHS.
The move is expected to benefit hundreds of patients each year.
Dostarlimab, which is sold under the brand name Jemperli, is an immunotherapy that works by attracting specific proteins on the surface of cancer cells to help the immune system attack them.
